𝔖 Bobbio Scriptorium

✦ LIBER ✦

194: Intravenous Busulfan in Children Prior to Haematological Stem Cell Transplantation, How Narrow is the Therapeutic Window?

✍ Scribed by I.H. Bartelink; R.G.M. Bredius; T.C.G. Egberts; M.M. Suttorp; M. Bierings; C. Knibbe; J. Zwaveling; J.J. Boelens

Book ID: 116280021
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 102 KB
Volume: 14
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2007.12.203

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Twice-Daily Intravenous (IV) Busulfan (B

Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days In Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Pharmacokinetically Similar to Q6 Hour Dosing in the Pediatric Population

✍ I. Waxman; M.C. Milone; M. Bhatia; L. Shaw; V. Moore; B. Tallamy; O. Militano; J 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

229: Twice-Daily Intravenous (IV) Busulf

229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults

✍ I. Waxman; M. Bhatia; M. Milone; L.M. Shaw; L. Baldinger; O. Militano; J. Garvin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB